Watchlist

Watchlist
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)
Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment
Analysis of top Seeking Alpha coverage: Akebia Today we will focus on Akebia Therapeutics ( AKBA ) after the company provided an update to investors on its late-stage vadadustat studies. Vadadustat is AKBAs lead product candidate being evaluated for the treatment of anemia assoc…
Akebia (AKBA) Presents At BIO CEO & Investor Conference - Slideshow
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this Read more …
Akebia and Otsuka tweak design of late-stage vadadustat studies, marketing approval in Japan may be 2021; shares down 2%
In an update to investors, Akebia Therapeutics ( AKBA -1.6% ) announces that it and commercialization partner Mitsubishi Tanabe Pharma have changed the designs of two Japan-based Phase 3 studies, FO2RWARD and TRILO2GY, evaluating vadadustat in patients with anemia associated with dialysi…
Akebia Therapeutics Provides Update on Vadadustat Development Program
-- Targets Full Enrollment for INNO 2 VATE and PRO 2 TECT by the End of 2018 -- -- Confirms Expectation of Top-Line Results for INNO 2 VATE and PRO 2 TECT in 2019, Subject to Accrual of MACE Events -- -- Enhances FO 2 RWARD and TRILO 2 GY Study Designs for …
Key healthcare events next week (continued)
Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more …
Akebia Therapeutics to Present at Upcoming February Investor Conferences
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at…
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted nine newly-hired employees options to purchase an aggregate of 53,550 shares of Ake…
Your Daily Pharma Scoop: ChemoCentryx Surges, Akebia Gets Positive News, Atara Prices Public Offering
Analysis of top Seeking Alpha coverage: ChemoCentryx Today we will discuss an update from ChemoCentryx ( CCXI ), which sent shares more than 30% higher in intra-day trading. ChemoCentryx is primarily focused on orphan and rare diseases. The companys lead product candidate is Avac…
Akebia's vadadustat shows positive results in Japan-based anemia study
A Phase 2 clinical trial conducted by Akebia Therapeutics ( AKBA +0.6% ) commercialization partner Mitsubishi Tanabe Pharma assessing vadadustat in Japanese patients with anemia associated with dialysis-dependent chronic kidney disease (DD-CKD) met its primary endpoint . The results were …
Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease
-- Data Consistent with Findings from Previous Studies -- -- Phase 3 Study of Non-Dialysis Patients in Japan Ongoing; Phase 3 Studies of Dialysis Patients to Begin in 2018 -- Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative t…
Akebia Therapeutics, Inc. (AKBA)